A randomised vaccine field trial in Kenya demonstrates protection against wildebeest-associated malignant catarrhal fever in cattle

Highlights•Wildebeest-associated malignant catarrhal fever is a fatal disease of cattle. •Seasonal disease caused by alcelaphine herpesvirus-1 with incidence up to 10% •Randomised placebo trial for the efficacy of alcelaphine herpesvirus-1 C500 vaccine. •The vaccine efficacy for controlling malignan...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2019-09, Vol.37 (40), p.5946-5953
Main Authors: Cook, Elizabeth, Russell, George, Grant, Dawn, Mutisya, Christine, Omoto, Lazarus, Dobson, Elizabeth, Lankester, Felix, Nene, Vishvanath
Format: Article
Language:English
Subjects:
Alcelaphine herpesvirus 1
Allergy and Immunology
Animal welfare
Cattle
Data collection
Disease
Enzyme-linked immunosorbent assay
Fever
Histopathology
Infections
Livestock
Malignant catarrhal fever
Pathology
Predation
Randomization
Vaccination
Vaccine efficacy
Vaccine field trial
Vaccines
Wildebeest
Wildlife conservation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights•Wildebeest-associated malignant catarrhal fever is a fatal disease of cattle. •Seasonal disease caused by alcelaphine herpesvirus-1 with incidence up to 10% •Randomised placebo trial for the efficacy of alcelaphine herpesvirus-1 C500 vaccine. •The vaccine efficacy for controlling malignant catarrhal fever in cattle over 80% •Safe and effective novel method for controlling malignant catarrhal fever in cattle.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.08.040